FindTrial
Sign In

177Lu-PP-F11N

DRUG2 trials

Sponsors

University Hospital, Basel, Switzerland

Conditions

Neuroendocrine Tumor GEP Grade 1-3Neuroendocrine Tumor of the Lung Grade 1 and 2Neuroendocrine Tumor of the Thymus Grade 1 and 2Thyroid Cancer, Medullary

Early Phase 1

177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer
CompletedNCT03647657
University Hospital, Basel, SwitzerlandThyroid Cancer, Medullary
Start: 2018-12-13End: 2021-12-14Updated: 2022-02-10

Phase 1

177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.
Active, not recruitingNCT02088645
University Hospital, Basel, SwitzerlandNeuroendocrine Tumor GEP Grade 1-3, Neuroendocrine Tumor of the Lung Grade 1 and 2, Neuroendocrine Tumor of the Thymus Grade 1 and 2 +1
Start: 2015-04-01End: 2028-04-01Target: 24Updated: 2026-05-01

Related Papers

In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study
EJNMMI Research2024-04-068 citations
The CCK-2 receptor agonist Lu-177-PP-F11N for PRRT of medullary thyroid cancer – Recent results of the phase 1 “LUMED” Study
Nuklearmedizin - NuclearMedicine2021-04-013 citations
SUN-334 Evaluation of the CCK-2 Receptor Agonist 177Lu-PP-F11N for PRRT of Medullary Thyroid Carcinoma: Results of a Phase 0 "Lumed" Study
Journal of the Endocrine Society2019-04-01